Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia.

Bellelli R, Vitagliano D, Federico G, Marotta P, Tamburrino A, Salerno P, Paciello O, Papparella S, Knauf JA, Fagin JA, Refetoff S, Troncone G, Santoro M.

Mol Cell Endocrinol. 2018 Jan 15;460:24-35. doi: 10.1016/j.mce.2017.06.023. Epub 2017 Jun 23.

PMID:
28652169
2.

SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.

Della Corte CM, Bellevicine C, Vicidomini G, Vitagliano D, Malapelle U, Accardo M, Fabozzi A, Fiorelli A, Fasano M, Papaccio F, Martinelli E, Troiani T, Troncone G, Santini M, Bianco R, Ciardiello F, Morgillo F.

Clin Cancer Res. 2015 Oct 15;21(20):4686-97. doi: 10.1158/1078-0432.CCR-14-3319. Epub 2015 Jun 29.

3.

Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.

Troiani T, Napolitano S, Martini G, Martinelli E, Cardone C, Normanno N, Vitagliano D, Morgillo F, Fenizia F, Lambiase M, Formisano L, Bianco R, Ciardiello D, Ciardiello F.

Clin Cancer Res. 2015 Sep 15;21(18):4153-64. doi: 10.1158/1078-0432.CCR-15-0211. Epub 2015 May 27.

4.

AXL is an oncotarget in human colorectal cancer.

Martinelli E, Martini G, Cardone C, Troiani T, Liguori G, Vitagliano D, Napolitano S, Morgillo F, Rinaldi B, Melillo RM, Liotti F, Nappi A, Bianco R, Berrino L, Ciuffreda LP, Ciardiello D, Iaffaioli V, Botti G, Ferraiolo F, Ciardiello F.

Oncotarget. 2015 Sep 15;6(27):23281-96.

5.

Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.

Napolitano S, Martini G, Rinaldi B, Martinelli E, Donniacuo M, Berrino L, Vitagliano D, Morgillo F, Barra G, De Palma R, Merolla F, Ciardiello F, Troiani T.

Clin Cancer Res. 2015 Jul 1;21(13):2975-83. doi: 10.1158/1078-0432.CCR-15-0020. Epub 2015 Apr 2.

6.

Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.

Troiani T, Napolitano S, Vitagliano D, Morgillo F, Capasso A, Sforza V, Nappi A, Ciardiello D, Ciardiello F, Martinelli E.

Clin Cancer Res. 2014 Jul 15;20(14):3775-86. doi: 10.1158/1078-0432.CCR-13-2181. Epub 2014 May 8.

7.

Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.

Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'Aiuto E, Berrino L, Bianco R, Ciardiello F.

Clin Cancer Res. 2013 Dec 15;19(24):6751-65. doi: 10.1158/1078-0432.CCR-13-0423. Epub 2013 Oct 11.

8.

Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.

Morgillo F, Sasso FC, Della Corte CM, Vitagliano D, D'Aiuto E, Troiani T, Martinelli E, De Vita F, Orditura M, De Palma R, Ciardiello F.

Clin Cancer Res. 2013 Jul 1;19(13):3508-19. doi: 10.1158/1078-0432.CCR-12-2777. Epub 2013 May 21.

9.

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.

Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F.

Int J Cancer. 2013 Nov;133(9):2089-101. doi: 10.1002/ijc.28236. Epub 2013 May 29.

10.

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.

Troiani T, Vecchione L, Martinelli E, Capasso A, Costantino S, Ciuffreda LP, Morgillo F, Vitagliano D, D'Aiuto E, De Palma R, Tejpar S, Van Cutsem E, De Lorenzi M, Caraglia M, Berrino L, Ciardiello F.

Br J Cancer. 2012 May 8;106(10):1648-59. doi: 10.1038/bjc.2012.129.

11.

Novel candidate genes of thyroid tumourigenesis identified in Trk-T1 transgenic mice.

Heiliger KJ, Hess J, Vitagliano D, Salerno P, Braselmann H, Salvatore G, Ugolini C, Summerer I, Bogdanova T, Unger K, Thomas G, Santoro M, Zitzelsberger H.

Endocr Relat Cancer. 2012 May 24;19(3):409-21. doi: 10.1530/ERC-11-0387. Print 2012 Jun.

12.

The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.

Vitagliano D, De Falco V, Tamburrino A, Coluzzi S, Troncone G, Chiappetta G, Ciardiello F, Tortora G, Fagin JA, Ryan AJ, Carlomagno F, Santoro M.

Endocr Relat Cancer. 2010 Nov 30;18(1):1-11. doi: 10.1677/ERC-09-0292. Print 2011 Feb.

13.

Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.

Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP, Tuccillo C, Vecchione L, Capasso A, Orditura M, De Vita F, Eckhardt SG, Santoro M, Berrino L, Ciardiello F.

Clin Cancer Res. 2010 Oct 15;16(20):4990-5001. doi: 10.1158/1078-0432.CCR-10-0923. Epub 2010 Sep 1.

14.

The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.

Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R, Caravatti G, Fabbro D, Lane HA, Fagin JA.

Cancer Res. 2007 Jul 15;67(14):6956-64.

15.

Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas.

Vitagliano D, Portella G, Troncone G, Francione A, Rossi C, Bruno A, Giorgini A, Coluzzi S, Nappi TC, Rothstein JL, Pasquinelli R, Chiappetta G, Terracciano D, Macchia V, Melillo RM, Fusco A, Santoro M.

Oncogene. 2006 Aug 31;25(39):5467-74. Epub 2006 Jun 19.

PMID:
16785999
16.

Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells.

Vitagliano D, Carlomagno F, Motti ML, Viglietto G, Nikiforov YE, Nikiforova MN, Hershman JM, Ryan AJ, Fusco A, Melillo RM, Santoro M.

Cancer Res. 2004 Jun 1;64(11):3823-9.

17.

H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization.

Celetti A, Cerrato A, Merolla F, Vitagliano D, Vecchio G, Grieco M.

Oncogene. 2004 Jan 8;23(1):109-21.

PMID:
14712216
18.

Genetic alterations in differentiated thyroid cancer: what can be expected for gene expression profiling of thyroid carcinomas.

Santoro M, Melillo RM, Carlomagno F, Castellone MD, Vitagliano D, Guida T, Vecchio G, Fusco A.

Ann Endocrinol (Paris). 2003 Feb;64(1):62-3. Review. No abstract available.

PMID:
12707638
19.

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G.

Clin Cancer Res. 2003 Apr;9(4):1546-56.

20.

Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).

Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo RM, Fusco A, Santoro M.

J Clin Endocrinol Metab. 2003 Apr;88(4):1897-902.

PMID:
12679489
21.

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M.

Cancer Res. 2002 Dec 15;62(24):7284-90.

22.

ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines.

Portella G, Scala S, Vitagliano D, Vecchio G, Fusco A.

J Clin Endocrinol Metab. 2002 Jun;87(6):2525-31.

PMID:
12050209
23.

The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes.

Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, Gazit A, Levitzki A, Santoro M.

Cancer Res. 2002 Feb 15;62(4):1077-82.

24.

HMGI-C gene expression is not required for in vivo thyroid cell transformation.

Scala S, Portella G, Vitagliano D, Ledent C, Chiappetta G, Giancotti V, Dumont J, Fusco A.

Carcinogenesis. 2001 Feb;22(2):251-6.

PMID:
11181445
25.

Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells.

Portella G, Vitagliano D, Borselli C, Melillo RM, Salvatore D, Rothstein JL, Vecchio G, Fusco A, Santoro M.

Oncol Res. 1999;11(9):421-7.

PMID:
10821536
26.

TPA induces a block of differentiation and increases the susceptibility to neoplastic transformation of a rat thyroid epithelial cell line.

Portella G, Vitagliano D, Li Z, Sferratore F, Santoro M, Vecchio G, Fusco A.

Oncol Res. 1998;10(9):441-7.

PMID:
10223619
27.

Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug-induced chorea.

Sage JI, Mark MH, McHale DM, Sonsalla PK, Vitagliano D.

Ann Neurol. 1991 Jun;29(6):623-8.

PMID:
1892365
28.

Complex dystonia of Parkinson's disease: clinical features and relation to plasma levodopa profile.

McHale DM, Sage JI, Sonsalla PK, Vitagliano D.

Clin Neuropharmacol. 1990 Apr;13(2):164-70.

PMID:
2328507
29.

Continuous levodopa infusions to treat complex dystonia in Parkinson's disease.

Sage JI, McHale DM, Sonsalla P, Vitagliano D, Heikkila RE.

Neurology. 1989 Jul;39(7):888-91.

PMID:
2472582

Supplemental Content

Loading ...
Support Center